SCHEMBL3762909

SCHEMBL3762909

O=S(=O)(Nc1ccccc1)c1cccc(C(F)(F)F)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 2/20 0.77
NR3C1 P04150 1/20 0.77
AR P10275 1/20 0.77
ESR2 Q92731 1/20 0.77
TSHR P16473 1/20 0.70
KMT2A Q03164 4/20 0.64
MEN1 O00255 3/20 0.64
GAA P10253 2/20 0.64
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64
MMP1 P03956 1/20 0.64
MMP2 P08253 1/20 0.64
MMP9 P14780 1/20 0.64
MMP8 P22894 1/20 0.64
MMP13 P45452 1/20 0.64
HSD17B2 P37059 1/20 0.63
FFAR1 O14842 1/20 0.62
CDK1 P06493 1/20 0.62
CCNB1 P14635 1/20 0.62
CCNA2 P20248 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL121452 0.90 CDK1 (0.76) PGRNR3C1ARESR2TSHR
SCHEMBL7572806 0.88 NR3C1 (0.69) PGRNR3C1ARESR2TSHR
SCHEMBL97543 0.86 NR3C1 (0.67) PGRNR3C1ARESR2TSHR
SCHEMBL5037026 0.86 NR3C1 (0.64) PGRNR3C1ARESR2TSHR
SCHEMBL7572556 0.86 PGR (0.67) PGRNR3C1ARESR2TSHR
SCHEMBL7592771 0.85 MEN1 (0.74) PGRNR3C1ARESR2TSHR
SCHEMBL19065106 0.85 TSHR (0.64) PGRNR3C1ARESR2TSHR
SCHEMBL22633492 0.84 GAA (0.68) PGRNR3C1ARESR2TSHR
SCHEMBL5040432 0.83 TSHR (0.61) PGRNR3C1ARESR2TSHR
SCHEMBL8081768 0.82 KEAP1 (0.79) PGRKMT2AMEN1GAACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311741-A1 Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents INHIBOX LTD. (GB) 2010-12-09 US disclosed
US-20100311741-A1 Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents INHIBOX LTD. (GB) 2010-12-09 US disclosed
WO-2008142376-A1 BICYCLOSULFONYL ACID (BCSA) COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS INHIBOX LTD. (GB) 2008-11-27 WO disclosed
EP-1239852-A2 BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS Arrow Therapeutics Limited (GB) 2002-09-18 EP disclosed
WO-2001028537-A2 BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS ARROW THERAPEUTICS LIMITED (GB) 2001-04-26 WO disclosed
EP-0306222-A2 Benzenesulfonanilide derivatives and fungicides for agriculture and horticulture HOKKO CHEMICAL INDUSTRY CO., LTD (JP) 1989-03-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311741-A1 Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents TNF, CS, COASY PGR 2436/4885NR3C1 1789/4885AR 2082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.